Τίτλος:
ESCMID guideline for the diagnosis and management of Candida diseases 2012: Prevention and management of invasive infections in neonates and children caused by Candida spp.
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Invasive candidiasis (IC) is a relatively common syndrome in neonates and children and is associated with significant morbidity and mortality. These guidelines provide recommendations for the prevention and treatment of IC in neonates and children. Appropriate agents for the prevention of IC in neonates at high risk include fluconazole (A-I), nystatin (B-II) or lactoferrin±Lactobacillus (B-II). The treatment of IC in neonates is complicated by the high likelihood of disseminated disease, including the possibility of infection within the central nervous system. Amphotericin B deoxycholate (B-II), liposomal amphotericin B (B-II), amphotericin B lipid complex (ABLC) (C-II), fluconazole (B-II), micafungin (B-II) and caspofungin (C-II) can all be potentially used. Recommendations for the prevention of IC in children are largely extrapolated from studies performed in adults with concomitant pharmacokinetic data and models in children. For allogeneic HSCT recipients, fluconazole (A-I), voriconazole (A-I), micafungin (A-I), itraconazole (B-II) and posaconazole (B-II) can all be used. Similar recommendations are made for the prevention of IC in children in other risk groups. With several exceptions, recommendations for the treatment of IC in children are extrapolated from adult studies, with concomitant pharmacokinetic studies. Amphotericin B deoxycholate (C-I), liposomal amphotericin B (A-I), ABLC (B-II), micafungin (A-I), caspofungin (A-I), anidulafungin (B-II), fluconazole (B-I) and voriconazole (B-I) can all be used. © 2012 The Authors. Clinical Microbiology and Infection © 2012 European Society of Clinical Microbiology and Infectious Diseases.
Συγγραφείς:
Hope, W.W.
Castagnola, E.
Groll, A.H.
Roilides, E.
Akova, M.
Arendrup, M.C.
Arikan-Akdagli, S.
Bassetti, M.
Bille, J.
Cornely, O.A.
Cuenca-Estrella, M.
Donnelly, J.P.
Garbino, J.
Herbrecht, R.
Jensen, H.E.
Kullberg, B.J.
Lass-Flörl, C.
Lortholary, O.
Meersseman, W.
Petrikkos, G.
Richardson, M.D.
Verweij, P.E.
Viscoli, C.
Ullmann, A.J.
Περιοδικό:
Clinical Microbiology and Infection
Εκδότης:
Wiley-Blackwell Publishing Ltd
Αριθμός / τεύχος:
SUPPL.7
Λέξεις-κλειδιά:
amphotericin B deoxycholate; amphotericin B lipid complex; anidulafungin; caspofungin; fluconazole; itraconazole; lactoferrin; micafungin; miconazole; nystatin; posaconazole; vincristine; voriconazole; antifungal agent, acute granulocytic leukemia; acute lymphoblastic leukemia; allogeneic hematopoietic stem cell transplantation; antifungal activity; area under the curve; article; autologous hematopoietic stem cell transplantation; cancer chemotherapy; Candida; Candida albicans; Candida glabrata; Candida krusei; Candida parapsilosis; Candida tropicalis; central nervous system infection; childhood disease; childhood mortality; dose response; drug blood level; drug dose increase; drug efficacy; drug formulation; drug megadose; drug monitoring; drug safety; extremely low birth weight; fungal colonization; human; invasive candidiasis; Lactobacillus rhamnosus; loading drug dose; long term care; meningoencephalitis; meta analysis (topic); nephrotoxicity; neurotoxicity; newborn infection; newborn intensive care; newborn mortality; nonhuman; practice guideline; priority journal; randomized controlled trial (topic); recommended drug dose; secondary prevention; single drug dose; treatment duration; adolescent; child; drug effect; infant; invasive candidiasis; isolation and purification; microbiology; newborn; pediatrics; preschool child, Adolescent; Antifungal Agents; Candida; Candidiasis, Invasive; Child; Child, Preschool; Humans; Infant; Infant, Newborn; Pediatrics
DOI:
10.1111/1469-0691.12040
